FDA Clears Padeliporfin VTP Ph 1 Clinical Program in Peripheral Lung Cancer
Barak Palatchi, CEO of ImPact Biotech, said, “We are delighted to receive FDA clearance to proceed with our planned clinical program for Padeliporfin VTP in Lung Cancer, further validating ImPact’s technology and the potential benefits our product could bring to patients with Peripheral Lung Cancer. Our strategy, focusing Padeliporfin VTP therapy on patients with limited treatment options, is proceeding according to our ambitious plan, with NSCLC as one of its major pillars. We are planning to demonstrate that Padeliporfin VTP offers a safe and effective treatment that will provide patients and their physicians with an additional therapy platform to target the disease. We are looking forward to exploring the possibility of offering Padeliporfin VTP to more patients coping with life threatening cancers.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome